Skip to main content
26 January 2021
Last updated:
Monday 25 January 2021

User account menu

  • Log in
  • Register & Subscribe

Search this site:

 

Primary links

  • Home
  • News
  • About MedNous
  • Research Directory
  • Contact Us

Novartis gets rights to allogeneic cell therapy

Saturday 21 November 2020
Country

Switzerland

Novartis has entered into a licencing and collaboration agreement with Australia-based Mesoblast Ltd to further develop and commercialise remestemcel-L, an allogeneic cell therapy for the treatment of a number of inflammatory disorders.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Clinical Research
Company News
Finance, Grants, Deals

Select a News Category

  • Clinical Research
  • Company News
  • Finance, Grants, Deals
  • IPR & Legal
  • Regenerative Medicine
  • Regulation & Policy
  • Research & University News

Recent Appointments

T-knife appoints Thomas Soloway as chief executive
Thursday January 21 2021
Domainex makes two executive appointments
Thursday January 21 2021
Richard Francis named CEO of Purespring
Tuesday January 19 2021
Klaas Zuideveld becomes CEO of Versameb
Saturday January 16 2021
MorphoSys appoints new CFO
Thursday January 7 2021

© 2021 Evernow Publishing Ltd. Powered by Drupal.